Hong Kong, 23 May 2025 – Mirxes Holding Company Limited (the “Company”; Stock code: 2629) marked a significant milestone today as its shares debuted on the Main Board of The Stock Exchange of Hong Kong Limited (HKEX), closing its first day of trade as a new biotech unicorn with a market capitalisation of HK$8.29 billion (US$1.06 billon).

Share of the Company, the first biotech firm from Southeast Asia to list on HKEX, were actively traded on the first day of listing, with an intraday high of HK$31.95 per Share and closed at HK$30.00 per Share, representing an increase of approximately 28.76% from the offer price of HK$23.30. Total trading volume was approximately 9.18 million shares today, representing an aggregate turnover of approximately HK$275.00 million.

Commenting on the positive reaction of the market, Dr Zhou Lihan, Co-Founder and CEO of Mirxes, said, “We are grateful to our dedicated team, valued partners, and supportive investors, each of whom has been pivotal to our growth and IPO success. For a biotech company like ours, the IPO is not the final destination, but a powerful catalyst igniting the journey ahead. Through the IPO, our mission to advance disease early detection and precision medicine through innovative miRNA-based solutions will surge forward with even greater momentum.”

Looking forward, the Company will continue to leverage on the global capital market to drive its innovation and growth. These include promoting molecular cancer screening and increasing penetration of GASTROClear in key markets; expanding its R&D capabilities; improving profitability, scalability, and speed to market by integrating its “end-to-end”capabilities; and developing a precision multi-omics clinical testing platform for Southeast Asia.